For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.
Among previously untreated patients, the objective response rate (ORR) was 85%, and...
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor...
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance...
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel coronavirus (COVID-19) pandemic. In light of emerging research showing many people are delaying cancer screenings and other health care needs, MD Anderson is reminding both cancer patients and the healthy public that it is safe to keep scheduled appointments for active treatment or routine care.
